Syros Pharmaceuticals Stock Price Prediction

SYRS Stock  USD 0.29  0.03  11.54%   
The RSI of Syros Pharmaceuticals' share price is above 70 at this time. This usually implies that the stock is becoming overbought or overvalued. The idea behind Relative Strength Index (RSI) is that it helps to track how fast people are buying or selling Syros, making its price go up or down.

Oversold Vs Overbought

74

 
Oversold
 
Overbought
The successful prediction of Syros Pharmaceuticals' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Syros Pharmaceuticals and does not consider all of the tangible or intangible factors available from Syros Pharmaceuticals' fundamental data. We analyze noise-free headlines and recent hype associated with Syros Pharmaceuticals, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting Syros Pharmaceuticals' stock price prediction:
EPS Estimate Next Quarter
(0.74)
EPS Estimate Current Year
(1.57)
EPS Estimate Next Year
(2.42)
Wall Street Target Price
1
EPS Estimate Current Quarter
(0.72)
Using Syros Pharmaceuticals hype-based prediction, you can estimate the value of Syros Pharmaceuticals from the perspective of Syros Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Syros Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying Syros because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Syros Pharmaceuticals after-hype prediction price

    
  USD 0.33  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Syros Pharmaceuticals Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Syros Stock please use our How to Invest in Syros Pharmaceuticals guide.
Intrinsic
Valuation
LowRealHigh
0.285.5319.96
Details
4 Analysts
Consensus
LowTargetHigh
19.3421.2523.59
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.42-0.39-0.37
Details

Syros Pharmaceuticals After-Hype Price Prediction Density Analysis

As far as predicting the price of Syros Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Syros Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Syros Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Syros Pharmaceuticals Estimiated After-Hype Price Volatility

In the context of predicting Syros Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Syros Pharmaceuticals' historical news coverage. Syros Pharmaceuticals' after-hype downside and upside margins for the prediction period are 0.02 and 14.76, respectively. We have considered Syros Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
0.29
0.33
After-hype Price
14.76
Upside
Syros Pharmaceuticals is dangerous at this time. Analysis and calculation of next after-hype price of Syros Pharmaceuticals is based on 3 months time horizon.

Syros Pharmaceuticals Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Syros Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Syros Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Syros Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.49 
14.43
  0.32 
  0.03 
9 Events / Month
15 Events / Month
In about 9 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
0.29
0.33
12.67 
2,220  
Notes

Syros Pharmaceuticals Hype Timeline

Syros Pharmaceuticals is at this time traded for 0.29. The entity has historical hype elasticity of -0.32, and average elasticity to hype of competition of 0.03. Syros is projected to increase in value after the next headline, with the price projected to jump to 0.33 or above. The average volatility of media hype impact on the company the price is over 100%. The price appreciation on the next news is projected to be 12.67%, whereas the daily expected return is at this time at -0.49%. The volatility of related hype on Syros Pharmaceuticals is about 20614.29%, with the expected price after the next announcement by competition of 0.32. Syros Pharmaceuticals currently holds 62.08 M in liabilities with Debt to Equity (D/E) ratio of 0.5, which is about average as compared to similar companies. Syros Pharmaceuticals has a current ratio of 6.44, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Syros Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.Given the investment horizon of 90 days the next projected press release will be in about 9 days.
Check out Syros Pharmaceuticals Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Syros Stock please use our How to Invest in Syros Pharmaceuticals guide.

Syros Pharmaceuticals Related Hype Analysis

Having access to credible news sources related to Syros Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Syros Pharmaceuticals' future price movements. Getting to know how Syros Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Syros Pharmaceuticals may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
SRZNSurrozen(0.75)5 per month 4.86  0.05  16.74 (7.91) 33.59 
BOLTBolt Biotherapeutics 0.03 8 per month 0.00 (0.15) 4.76 (4.48) 14.96 
LRMRLarimar Therapeutics(0.49)9 per month 0.00 (0.06) 10.87 (9.55) 26.71 
KROSKeros Therapeutics 0.52 8 per month 2.13  0.09  4.39 (4.31) 16.94 
KZRKezar Life Sciences 0.33 9 per month 3.01  0.06  8.11 (4.39) 51.13 
IDYAIdeaya Biosciences 0.02 7 per month 0.00 (0.22) 4.15 (5.09) 15.21 
SNDXSyndax Pharmaceuticals(0.06)10 per month 0.00 (0.1) 4.02 (4.33) 34.00 
XNCRXencor Inc 0.33 9 per month 1.36  0.15  5.39 (3.14) 26.75 
RGNXRegenxbio 0.16 10 per month 0.00 (0.07) 5.72 (7.20) 32.22 
CRNXCrinetics Pharmaceuticals 1.32 9 per month 2.43 (0.01) 3.67 (3.45) 16.75 
BDTXBlack Diamond Therapeutics 0.18 7 per month 0.00 (0.30) 5.56 (8.30) 19.51 
STOKStoke Therapeutics 0.46 10 per month 0.00 (0.09) 4.68 (6.99) 21.35 
FIXXHomology Medicines(0.01)2 per month 3.52  0.01  5.77 (5.61) 19.43 
HARPHarpoon Therapeutics 0.00 0 per month 3.28  0.09  9.59 (6.25) 22.48 
PASGPassage Bio(0.02)8 per month 0.00 (0.08) 9.33 (9.88) 25.50 
KTTAPasithea Therapeutics Corp(0.15)5 per month 0.00 (0.04) 8.27 (11.00) 68.44 
KRONKronos Bio(0.02)10 per month 0.00 (0.06) 5.56 (6.25) 16.20 
QNRXQuoin Pharmaceuticals Ltd 0.01 9 per month 6.71  0.03  17.65 (9.68) 74.46 
RNXTRenovoRx(0.09)4 per month 3.64  0.08  7.21 (5.17) 40.06 
SPROSpero Therapeutics 0.01 9 per month 0.00 (0.13) 3.79 (4.58) 14.92 
CHRSCoherus BioSciences(0.03)5 per month 0.00 (0.04) 7.62 (6.94) 34.15 
GRCLGracell Biotechnologies 0.00 0 per month 6.35  0.16  16.34 (6.25) 52.11 
NLTXNeoleukin Therapeutics(0.14)1 per month 0.00 (0.08) 4.05 (3.53) 27.84 

Syros Pharmaceuticals Additional Predictive Modules

Most predictive techniques to examine Syros price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Syros using various technical indicators. When you analyze Syros charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Syros Pharmaceuticals Predictive Indicators

The successful prediction of Syros Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Syros Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Syros Pharmaceuticals based on analysis of Syros Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Syros Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Syros Pharmaceuticals's related companies.
 2021 2022 2023 2024 (projected)
Days Sales Outstanding46.2941.5547.7945.4
PTB Ratio2.390.3613.2413.91

Story Coverage note for Syros Pharmaceuticals

The number of cover stories for Syros Pharmaceuticals depends on current market conditions and Syros Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Syros Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Syros Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Syros Pharmaceuticals Short Properties

Syros Pharmaceuticals' future price predictability will typically decrease when Syros Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Syros Pharmaceuticals often depends not only on the future outlook of the potential Syros Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Syros Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding28.3 M
Cash And Short Term Investments139.5 M

Additional Tools for Syros Stock Analysis

When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.